Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07946848
PHASE2

Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.

Sponsor: Immuneering Corporation

View on ClinicalTrials.gov

Summary

Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer

Official title: A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-12

Completion Date

2029-07

Last Updated

2026-11-19

Healthy Volunteers

No

Interventions

DRUG

Atebimetinib

Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg

BIOLOGICAL

Cemiplimab

Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks

DRUG

Carboplatin

AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4

DRUG

Pemetrexed (500 mg/m²)

500 mg/m² IV on Day 1 of Cycles 1-4

Locations (1)

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States